Mesa Laboratories (NASDAQ:MLAB) CFO Sells $123,853.21 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys sold 1,223 shares of Mesa Laboratories stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $101.27, for a total transaction of $123,853.21. Following the completion of the transaction, the chief financial officer directly owned 16,538 shares of the company’s stock, valued at approximately $1,674,803.26. This represents a 6.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Stock Performance

Mesa Laboratories stock traded down $4.85 during mid-day trading on Wednesday, reaching $94.84. The company’s stock had a trading volume of 154,655 shares, compared to its average volume of 136,917. The firm has a market cap of $523.96 million, a price-to-earnings ratio of 79.03 and a beta of 0.94. The business has a 50 day moving average price of $101.88 and a 200-day moving average price of $90.54. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. Mesa Laboratories, Inc. has a twelve month low of $55.45 and a twelve month high of $113.99.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The company had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same quarter in the previous year, the business posted ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Friday, May 29th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, May 29th. Mesa Laboratories’s dividend payout ratio (DPR) is presently 53.33%.

Institutional Investors Weigh In On Mesa Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after purchasing an additional 143 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Mesa Laboratories by 1.5% during the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after purchasing an additional 194 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 243 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Mesa Laboratories by 5.9% during the fourth quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier’s stock valued at $349,000 after purchasing an additional 248 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.